（来源：化妆品观察 品观） 根据公告披露，美丽田园2025年营收不低于30亿元，净利润不低于3.4亿元。这意味着，中国美容行业诞生了一家30亿级巨头。 1月19日，美丽田园医疗健康（02373.HK，以下简称"美丽田园"）发布2025年正面盈利预告。 2024年以来，美丽田园通过并购整合，已将中国高端美容行业前三大品牌（美丽田园、奈瑞儿、思妍丽）全部招致麾下。 1月20日，在2025年度业绩盈喜电话会上，美丽田园CFO周敏表示，预计2026年收入将超过40亿元，经调净利润不低于5亿元。同时，公司的中长期目标 是"五年收入翻倍、三年利润翻倍"。 营收、净利6年翻倍增长 根据正面盈利公告，美丽田园预计，其2025年收入不少于30亿元，较2024年同期增长不少于16%；经调净利润不少于3.8亿元，同比增长不少于40%；净利 润不少于3.4亿元，同比增长不少于34%。 回望过去6年，该公司的营收从2020年的15.03亿元升至2025年的不低于30亿元，仅在2022年受疫情影响有所下滑。 净利润方面，2020年至2025年，美丽田园净利润从1.52亿元增长至不少于3.4亿元，也实现了翻倍增长。 | स्टेसि | ...

Core Viewpoint - Meili Tianyuan Medical Health expects significant financial performance growth for the fiscal year ending December 31, 2025, with projected revenues of at least 3 billion yuan, representing a year-on-year increase of no less than 16% compared to 2024 [1] Financial Performance Summary - Projected revenue for 2025 is expected to be no less than 3 billion yuan, an increase of at least 16% from 2024 [1] - Adjusted net profit is anticipated to be at least 380 million yuan, reflecting a year-on-year growth of no less than 40% compared to 2024 [1] - Net profit is projected to be at least 340 million yuan, which is an increase of no less than 34% from 2024 [1] Growth Drivers Summary - The primary reasons for the performance improvement include accelerated external expansion and strong organic growth [1] - The acquisition of Narier, the second-ranked brand in China's beauty industry, has enhanced market share and contributed to revenue and profit growth [1] - Increased brand momentum and a growing customer base have driven organic revenue growth, while a higher proportion of high-margin medical business revenue has further boosted profit margins [1]

（文章来源：每日经济新闻） 每经AI快讯，美丽田园医疗健康(02373.HK)涨近5%，截至发稿涨4.74%，报26.5港元，成交额139.57万 港元。 ...

Core Viewpoint - Meili Tianyuan Medical Health (02373) anticipates significant revenue and profit growth for 2025, driven by both external expansion and strong internal growth [1] Group 1: Financial Projections - The company expects to achieve revenue of no less than RMB 3 billion in 2025, representing a year-on-year growth of no less than 16% [1] - Adjusted net profit is projected to be no less than RMB 380 million, with a year-on-year increase of no less than 40% [1] - Net profit is expected to reach no less than RMB 340 million, reflecting a year-on-year growth of no less than 34% [1] Group 2: Growth Drivers - The board attributes the performance improvement primarily to accelerated external expansion, including the acquisition of the second-ranked brand in China's beauty industry, Nairui'er, which enhances market share and boosts revenue and profit [1] - Strong internal growth is driven by increased brand momentum and a growing customer base, contributing to internal revenue growth [1] - The rising proportion of high-margin medical business revenue, combined with the release of operational efficiency, further drives profit margin growth [1]

消息面上，美丽田园医疗健康发布公告称，预期2025年实现收入不少于人民币30亿元，同比增长不少于 16%；经调整净利润不少于人民币3.8亿元，同比增长不少于40%；净利润不少于人民币3.4亿元，同比 增长不少于34%。 董事会认为业绩提升主要由于外延扩张加速：作为行业龙头加速行业整合进程，收购中国美容行业排名 第二的品牌奈瑞儿，提升市场占有率，增厚集团营收与利润；内生增长强劲，品牌势能扩大，客户数量 增长推动内生收入增长，以及高毛利医疗业务收入占比提高，叠加精细化运营效能释放，共同驱动利润 率进一步增长。 智通财经APP获悉，美丽田园医疗健康(02373)涨近5%，截至发稿，涨4.74%，报26.5港元，成交额 139.57万港元。 ...

Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) has announced a positive profit forecast for 2025, expecting revenue of at least 3 billion yuan, a year-on-year increase of no less than 16%, and a net profit of at least 3.4 billion yuan, reflecting strong resilience and growth potential amid economic fluctuations [1][3]. Group 1: Revenue and Profit Forecast - The company anticipates a revenue of no less than 3 billion yuan for 2025, representing a growth of at least 16% compared to 2024 [1]. - Adjusted net profit is expected to be no less than 3.8 billion yuan, indicating a year-on-year growth of at least 40% [1]. - Net profit is projected to be no less than 3.4 billion yuan, with a year-on-year increase of at least 34% [1]. Group 2: Strategic Expansion - The company is accelerating its external expansion through a dual growth strategy of "internal growth + external acquisitions," having successfully acquired the second-largest brand in China's beauty industry, Nairui'er, in 2024 [1]. - The integration of Nairui'er into Meili Tianyuan's brand matrix has significantly enhanced market share and business penetration in key areas of the Greater Bay Area [1]. - The acquisition has led to a strategic upgrade of the business model to a "dual beauty + dual healthcare" ecosystem, with Nairui'er’s adjusted net profit margin increasing from 6.5% before acquisition to 10.4% post-acquisition [1]. Group 3: Internal Growth and Market Position - Meili Tianyuan is capitalizing on the trend of "self-consumption" among women in high-tier cities, driving same-store revenue growth despite market challenges [3]. - The company is enhancing its medical business capabilities, with high-margin medical business revenue steadily increasing in 2025 [3]. - The store network has expanded to over 734 locations, capturing a significant market share in 20 first-tier and new first-tier cities [3]. Group 4: Future Strategies - The company will continue to implement its dual growth strategy of "internal growth + external acquisitions" and deepen the "dual beauty + dual healthcare" business model [5]. - A capital market value enhancement plan is set to be executed, aiming to create sustainable win-win outcomes for customers, shareholders, employees, and partners [5].

Group 1: Major Developments - 康耐特光学 (02276) and 歌尔光学 plan to establish a joint venture to expand the application market for customized lenses in AI/AR/VR/MR glasses [1] - 圣贝拉 (02508) and 云迹科技 signed a strategic cooperation framework agreement to explore the deep integration and application of artificial intelligence and robotics in high-demand home care scenarios [1] - KKCG Maritime intends to initiate a voluntary conditional partial public acquisition offer to acquire 15.4% of 法拉帝 (09638) shares [1] - 远大医药 (00512) announced that the new drug application for the innovative radiolabeled drug TLX591-CDx has been accepted by the China National Medical Products Administration [1] - 艾美疫苗 (06660) received approval to conduct clinical trials for a 20-valent pneumococcal polysaccharide conjugate vaccine [1] - 中国东方航空股份 (00670) sold the 凯迪克大厦 in Shanghai and related assets to 东航置业 for approximately 134 million yuan [1] - 佑驾创新 (02431) signed a memorandum of understanding with India's leading automotive parts manufacturer STL [1] - 南山铝业国际 (02610) plans to develop electrolytic aluminum and related raw materials and supporting businesses [1] Group 2: Financial Performance - 顺丰控股 (06936) reported a total revenue of 27.339 billion yuan from its express logistics, supply chain, and international businesses in December, representing a year-on-year increase of 3.41% [2] - 美丽田园医疗健康 (02373) issued a profit warning, expecting adjusted net profit for 2025 to be no less than 380 million yuan, a year-on-year increase of at least 40% [2] - 中国太平 (00966) issued a profit warning, anticipating a year-on-year increase of approximately 215% to 225% in shareholder profit for the 2025 fiscal year [2] - 吉宏股份 (02603) issued a profit warning, expecting a net profit attributable to shareholders of approximately 273 million to 291 million yuan for 2025, a year-on-year increase of 50% to 60% [2] - 兖煤澳大利亚 (03668) reported a fourth-quarter coal sales volume of 10.8 million tons, a year-on-year increase of 4% [2] - 兖矿能源 (01171) reported a fourth-quarter commodity coal production of 46.51 million tons, a year-on-year increase of 4.4% [2] - 深圳控股 (00604) projected a total contract sales amount of approximately 13.311 billion yuan for 2025, a year-on-year decrease of 21.55% [2] - 上海石油化工股份 (00338) issued a profit warning, expecting a net loss attributable to shareholders of approximately 1.289 billion to 1.576 billion yuan for 2025, indicating a shift from profit to loss [2] - 上海石油化工股份 (00338) reported gasoline sales revenue of 24.656 billion yuan for 2025 [2]

Core Viewpoint - Meili Tianyuan Healthcare (02373) expects to achieve a revenue of no less than RMB 3 billion in 2025, representing a growth of at least 16% compared to the same period in 2024, and an adjusted net profit of no less than RMB 380 million, reflecting a growth of at least 40% year-on-year [1] Group 1: Financial Projections - The company anticipates a net profit of no less than RMB 340 million in 2025, which is an increase of at least 34% compared to 2024 [1] - Revenue target for 2025 is set at no less than RMB 3 billion, indicating a growth of at least 16% from 2024 [1] - Adjusted net profit is projected to be no less than RMB 380 million, marking a growth of at least 40% year-on-year [1] Group 2: Reasons for Performance Improvement - Accelerated external expansion is a key driver, highlighted by the acquisition of the second-ranked brand in China's beauty industry, Nairui'er, which enhances market share and boosts revenue and profit [1] - Strong organic growth is noted, driven by an increase in brand momentum and customer numbers, leading to higher internal revenue growth and an increased proportion of high-margin medical business revenue [1] - The company emphasizes a dual strategy of "organic growth + external acquisitions" and aims to deepen its "dual beauty + dual healthcare" business model [1]

Core Viewpoint - The company anticipates achieving a revenue of no less than RMB 3 billion by 2025, representing a growth of at least 16% compared to the same period in 2024, alongside adjusted net profits of no less than RMB 3.8 billion, reflecting a growth of at least 40% [1] Group 1: Financial Projections - Expected revenue for 2025 is at least RMB 3 billion, a growth of no less than 16% from 2024 [1] - Adjusted net profit is projected to be no less than RMB 3.8 billion, indicating a growth of at least 40% compared to 2024 [1] - Net profit is anticipated to be no less than RMB 3.4 billion, with a growth of at least 34% from 2024 [1] Group 2: Reasons for Performance Improvement - Accelerated external expansion is a key driver, highlighted by the acquisition of the second-ranked brand in China's beauty industry, Nairui'er, which enhances market share and boosts revenue and profit [1] - Strong internal growth is noted, with an increase in brand momentum and customer numbers driving organic revenue growth, alongside a higher proportion of high-margin medical business revenue [1] - The company emphasizes a dual strategy of "internal growth + external acquisition" and aims to deepen its "dual beauty + dual healthcare" business model [1]

格隆汇1月19日丨美丽田园医疗健康(02373.HK)公告，根据对集团截至2025年12月31日止年度(「报告期 间」)之未经审核综合管理账目之初步评估及董事会现时可得资料，集团预期录得以下财务业绩：(i)收 入不少于人民币30亿元，较2024年同期相比增长不少于16%；(ii)经调整净利润不少于人民币380百万 元，较2024年同期相比增长不少於40%；及(iii)净利润不少于人民币3.4亿元，较2024年同期相比增长不 少于34%。 ...